Share on StockTwits

Shares of Cempra Holdings (NASDAQ:CEMP) have received an average rating of “Buy” from the ten analysts that are presently covering the stock, AnalystRatings.NET reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $15.63.

Cempra Holdings (NASDAQ:CEMP) traded up 5.12% during mid-day trading on Friday, hitting $10.9638. The stock had a trading volume of 71,122 shares. Cempra Holdings has a one year low of $6.95 and a one year high of $15.39. The stock has a 50-day moving average of $9.23 and a 200-day moving average of $11.30. The company’s market cap is $364.0 million.

Cempra Holdings (NASDAQ:CEMP) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.03. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.10 million. On average, analysts predict that Cempra Holdings will post $-2.22 earnings per share for the current fiscal year.

A number of research firms have recently commented on CEMP. Analysts at Gabelli initiated coverage on shares of Cempra Holdings in a research note on Friday. They set a “buy” rating on the stock. Analysts at Barclays initiated coverage on shares of Cempra Holdings in a research note on Tuesday, April 8th. They set an “equal weight” rating and a $13.00 price target on the stock.

Cempra, Inc, formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.